A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086)
This is a two-part study of pembrolizumab monotherapy in participants with metastatic
triple-negative breast cancer (mTNBC). Part 1 of the study will examine the efficacy and
safety of pembrolizumab monotherapy as first line or above treatment. Part 2 of the study,
if done, will expand the investigation of pembrolizumab treatment in a subgroup of
participants from Part 1 and will only start after enrollment in Part 1 has been completed.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society